1529-0131/asset/cover.gif?v=1&s=104d5c2bb8ef72deba26790b855af7ab80697a0e "Arthritis & Rheumatism")
Dr. Fitzcharles has received consulting fees, speaking fees, and/or honoraria from Eli Lilly, Janssen, Pfizer, and Purdue Pharma (less than $10,000 each) and has provided expert testimony regarding pain related to rheumatic conditions for the plaintiff and the defense in court trials.
1529-0131/asset/olbannerleft.gif?v=1&s=897b81612b4ad6cae003112184adc709261d5f61)
1529-0131/asset/olbannerright.gif?v=1&s=04654f5ea3cbb01656383e0c0d04b16fd0a9a896)
Review
Clinical implications for cannabinoid use in the rheumatic diseases: Potential for help or harm?
Article first published online: 27 JUL 2012
DOI: 10.1002/art.34522
Copyright © 2012 by the American College of Rheumatology
Additional Information
How to Cite
Fitzcharles, M.-A., McDougall, J., Ste-Marie, P. A. and Padjen, I. (2012), Clinical implications for cannabinoid use in the rheumatic diseases: Potential for help or harm?. Arthritis & Rheumatism, 64: 2417–2425. doi: 10.1002/art.34522
- †
Dr. Fitzcharles has received consulting fees, speaking fees, and/or honoraria from Eli Lilly, Janssen, Pfizer, and Purdue Pharma (less than $10,000 each) and has provided expert testimony regarding pain related to rheumatic conditions for the plaintiff and the defense in court trials.
- ‡
Dr. McDougall has received consulting fees from Eli Lilly (less than $10,000).
Publication History
- Issue published online: 27 JUL 2012
- Article first published online: 27 JUL 2012
- Accepted manuscript online: 17 MAY 2012 02:29PM EST
- Manuscript Accepted: 24 APR 2012
- Manuscript Received: 27 DEC 2011
- Abstract
- Article
- References
- Cited By
First page of article
